Optimal management of mantle cell lymphoma in the primary setting. Issue 9 (2nd September 2019)

• Record Type: Journal Article
• Authors: Tang, Catherine; Kuruvilla, John
• Is Part Of: Expert review of hematology. Volume 12:Issue 9(2019)
• Page Start: 715
• Page End: 721
• Publication Date: 2019-09-02
• Subjects: Mantle cell lymphoma -- autologous stem cell transplant -- minimal residual disease -- chemotherapy -- lymphoma; Hematology -- Periodicals; 616.15005
• DOI: 10.1080/17474086.2019.1639501
• Languages: English
• ISSNs: 1747-4086

Abstract

ABSTRACT: Introduction : The management of mantle cell lymphoma (MCL) has significantly improved since the use of intensified induction and autologous stem cell transplant consolidation. Evolving developments in minimal residual disease detection and novel agent therapy are now challenging this frontline treatment paradigm. Areas covered : This review discusses both the established role of induction and transplant consolidation in MCL, followed by evolving concepts in the use of novel agents in the frontline setting, and the use of minimal residual disease as a driver of MCL management. Expert opinion : In an era of novel agents and improved biologic understanding of MCL, our goal for frontline management should evolve toward personalized therapy for individual patients to maximize efficacy and survival whilst minimizing treatment-related toxicities.